Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma.
10.4174/jkss.2011.81.6.394
- Author:
Kyoung Won YOON
1
;
Jin Seok HEO
;
Dong Wook CHOI
;
Seoung Ho CHOI
Author Information
1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jinseok.heo@samsung.com
- Publication Type:Original Article
- Keywords:
Pancreatic neoplasms;
Bilirubin;
CA19-9 antigen
- MeSH:
Adenocarcinoma;
Bilirubin;
Electronic Health Records;
Follow-Up Studies;
Humans;
Multivariate Analysis;
Pancreatic Ducts;
Pancreatic Neoplasms;
Retrospective Studies;
Telephone
- From:Journal of the Korean Surgical Society
2011;81(6):394-401
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Some patients who undergo surgical resection of pancreatic cancer survive longer than other patients. The purpose of this study was to identify the factors that affect long-term survival after resection of histopathologically confirmed pancreatic ductal adenocarcinoma. METHODS: A single-center, retrospective study was conducted among 164 patients who underwent surgical resection of pancreatic cancer, between May 1995 and December 2004. The patient follow-up process was conducted via telephone survey and review of electronic medical records for at least 5 years or until death. RESULTS: We compared patients with long-term (> or =60 months, n = 19) and short-term survival (<60 months, n = 145). Resection margin status, differentiation of the tumor, tumor stage, pre-operative serum level of albumin, total bilirubin and carbohydrate antigen (CA) 19-9 level are related with survival difference (all factors, P < 0.05). Multivariate analysis revealed that a pre-operative serum total bilirubin level <7 mg/dL and a pre-operative serum CA19-9 level <37 U/mL is a statistically significant prognostic factor for long-term survival. CONCLUSION: The preoperative serum total bilirubin and serum CA19-9 levels are associated with long-term survival after surgical resection of pancreatic cancer.
